Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the safety and efficacy of etanercept in comparison
with placebo in a double-blind, parallel, randomized fashion in subjects with idiopathic
pulmonary fibrosis (IPF) who failed previous therapy. The treatment period will be up to 1
year. The primary objective is evaluation of safety and efficacy. Secondary: The secondary
objective is to evaluate quality of life (QoL) and pharmacokinetics (PK).